Alterity Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Alterity Therapeutics (ATHE).

Price Target Range — 5 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$11Upside to Avg. PT+378.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 15, 2026	Lake Street	Thomas Flaten	Initiate	Buy	$10
Aug 11, 2026	Craig-Hallum	Adam Vogel	Initiate	Buy	$12
Jun 30, 2026	Jones Trading	Debanjana Chatterjee	Initiate	Buy	$16
Jun 16, 2026	Ladenburg Thalmann	Caroline Palomeque	Assumes	Buy	$10
Dec 17, 2025	Canaccord Genuity	—	Initiate	Speculative Buy	—
Jan 30, 2025	Maxim Group	Jason McCarthy	PT Raise	Buy	$8→$12
Dec 12, 2024	Maxim Group	Jason McCarthy	Initiate	Buy	$8
Mar 7, 2024	Benchmark	Robert Wasserman	Maintained	Speculative Buy	$4

Analyst Ratings News

PRO
Lake Street Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $10

Lake Street analyst Thomas Flaten initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $10.

Benzinga Newsdesk

PRO
Craig-Hallum Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $12

Craig-Hallum analyst Adam Vogel initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
Jones Trading Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $16

Jones Trading analyst Debanjana Chatterjee initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $16.

Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on Alterity Therapeutics, Raises Price Target to $12

Maxim Group analyst Jason McCarthy maintains Alterity Therapeutics (NASDAQ:ATHE) with a Buy and raises the price target from $8 to $12.

Benzinga Newsdesk

PRO
Maxim Group Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $8

Maxim Group analyst Jason McCarthy initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $8.

Benzinga Newsdesk

Alterity Up on Interim Data From Advance MSA Study

Shares of Alterity Therapeutics (NASDAQ: ATHE) were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for treating patients with multiple system atrophy, a rare neurodegenerative disease.

Zacks

Alterity Therapeutics Ltd

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Alterity Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Lake Street Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $10

PRO
Craig-Hallum Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $12

PRO
Jones Trading Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $16

PRO
Maxim Group Maintains Buy on Alterity Therapeutics, Raises Price Target to $12

PRO
Maxim Group Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $8

Alterity Up on Interim Data From Advance MSA Study

People Also Watch

People Also Watch

Alterity Therapeutics Ltd

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Alterity Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLake Street Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $10

PROCraig-Hallum Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $12

PROJones Trading Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $16

PROMaxim Group Maintains Buy on Alterity Therapeutics, Raises Price Target to $12

PROMaxim Group Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $8

Alterity Up on Interim Data From Advance MSA Study

People Also Watch

People Also Watch

PRO
Lake Street Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $10

PRO
Craig-Hallum Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $12

PRO
Jones Trading Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $16

PRO
Maxim Group Maintains Buy on Alterity Therapeutics, Raises Price Target to $12

PRO
Maxim Group Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $8